Results build on LATITUDE study and robust body of evidence supporting investigational use.
GSK announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager from Chimagen Biosciences.
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
Longer survival achieved with fewer severe treatment-related side effects versus comparator...
New presentation offers convenient administration of GSK's shingles vaccine
Phase III trial to start in September 2026
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.
First global approval for Hibsago